Floatz logo

Zofran

Plasma Cell Leukemia

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3B
cc-5013
National Cancer Institute (NCI)
Phase 3B
Evomela
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Zofran is also rated in:

NauseaDormant
BBB
Indicative ·
73 / 100
View asset →
VomitingDormant
BBB
Indicative ·
73 / 100
View asset →
Non-Hodgkin's LymphomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →